BioNTech is upping its bet on a PD-L1xVEGF-A bispecific, paying $800 million upfront to buy its Chinese partner Biotheus ...
BioNTech said that it is acquiring the Chinese drugmaker Biotheus for $800 million to bolster its cancer strategy. The two ...
VEGF bispecifics. | Merck and BioNTech are buying Chinese biotechs to gain PD-(L)1/VEGF bispecifics. AstraZeneca's CEO argued ...
On Wednesday, BioNTech SE (NASDAQ:BNTX) agreed to acquire Biotheus, a clinical-stage biotechnology company focused on ...
GlobalData on MSN3d
BioNTech signs agreement to acquire BiotheusBioNTech has signed a definitive agreement to acquire Biotheus to obtain complete worldwide rights to BNT327/PM8002, a ...
German drugmaker BioNTech has agreed to acquire Chinese biotech company Biotheus to support its oncology strategy and gain ...
Biotheus’ antibody drug targets PD-L1 and VEGF, a design that’s high on drugmakers’ radars after the success of Summit ...
BioNTech is investing in a promising space in oncology by acquiring Biotheus’ PD-L1 and VEGF bispecific antibody.
Analysts have set 12-month price targets for BioNTech, revealing an average target of $132.24, a high estimate of $171.00, ...
BioNTech said that BNT327 has the "potential to replace current checkpoint inhibitor standard of care treatments for solid ...
BioNTech SE (BNTX) announced Tuesday that it has signed an agreement to acquire Biotheus, a clinical-stage biotechnology company ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback